Rhythm Pharmaceuticals Statistics
Total Valuation
RYTM has a market cap or net worth of $4.33 billion. The enterprise value is $4.13 billion.
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, before market open.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RYTM has 63.62 million shares outstanding. The number of shares has increased by 5.45% in one year.
| Current Share Class | 63.62M |
| Shares Outstanding | 63.62M |
| Shares Change (YoY) | +5.45% |
| Shares Change (QoQ) | +2.37% |
| Owned by Insiders (%) | 0.65% |
| Owned by Institutions (%) | 84.20% |
| Float | 51.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.72 |
| Forward PS | 21.36 |
| PB Ratio | 228.25 |
| P/TBV Ratio | 333.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 30.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.30, with a Debt / Equity ratio of 0.70.
| Current Ratio | 3.30 |
| Quick Ratio | 2.97 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.47 |
Financial Efficiency
Return on equity (ROE) is -150.20% and return on invested capital (ROIC) is -74.16%.
| Return on Equity (ROE) | -150.20% |
| Return on Assets (ROA) | -51.33% |
| Return on Invested Capital (ROIC) | -74.16% |
| Return on Capital Employed (ROCE) | -96.42% |
| Revenue Per Employee | $483,615 |
| Profits Per Employee | -$614,912 |
| Employee Count | 283 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.02 |
Taxes
In the past 12 months, RYTM has paid $126,000 in taxes.
| Income Tax | 126,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +70.62% in the last 52 weeks. The beta is 2.30, so RYTM's price volatility has been higher than the market average.
| Beta (5Y) | 2.30 |
| 52-Week Price Change | +70.62% |
| 50-Day Moving Average | 60.19 |
| 200-Day Moving Average | 55.71 |
| Relative Strength Index (RSI) | 64.14 |
| Average Volume (20 Days) | 591,955 |
Short Selling Information
The latest short interest is 5.07 million, so 7.97% of the outstanding shares have been sold short.
| Short Interest | 5.07M |
| Short Previous Month | 4.85M |
| Short % of Shares Out | 7.97% |
| Short % of Float | 9.84% |
| Short Ratio (days to cover) | 7.26 |
Income Statement
In the last 12 months, RYTM had revenue of $136.86 million and -$174.02 million in losses. Loss per share was -$2.82.
| Revenue | 136.86M |
| Gross Profit | 122.65M |
| Operating Income | -265.02M |
| Pretax Income | -258.09M |
| Net Income | -174.02M |
| EBITDA | -263.48M |
| EBIT | -265.02M |
| Loss Per Share | -$2.82 |
Full Income StatementBalance Sheet
The company has $314.49 million in cash and $113.59 million in debt, giving a net cash position of $200.90 million or $3.16 per share.
| Cash & Cash Equivalents | 314.49M |
| Total Debt | 113.59M |
| Net Cash | 200.90M |
| Net Cash Per Share | $3.16 |
| Equity (Book Value) | 163.09M |
| Book Value Per Share | 0.30 |
| Working Capital | 257.47M |
Full Balance SheetCash Flow
| Operating Cash Flow | -113.49M |
| Capital Expenditures | n/a |
| Free Cash Flow | -113.49M |
| FCF Per Share | -$1.78 |
Full Cash Flow StatementMargins
Gross margin is 89.62%, with operating and profit margins of -193.64% and -123.28%.
| Gross Margin | 89.62% |
| Operating Margin | -193.64% |
| Pretax Margin | -123.19% |
| Profit Margin | -123.28% |
| EBITDA Margin | -192.51% |
| EBIT Margin | -193.64% |
| FCF Margin | n/a |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.45% |
| Shareholder Yield | -5.45% |
| Earnings Yield | -4.02% |
| FCF Yield | -2.62% |
Dividend DetailsAnalyst Forecast
The average price target for RYTM is $76.75, which is 12.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $76.75 |
| Price Target Difference | 12.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 63.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RYTM has an Altman Z-Score of 2.7 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.7 |
| Piotroski F-Score | 3 |